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Abstract
Oral tolerance induction is thought to depend on special antigen
presenting cells in the gut. A new report in the previous issue of
Arthritis Research & Therapy supports this idea by demonstrating
that indoleamine 2,3-dioxygenase-expressing dendritic cells in
Peyer’s patches from orally tolerized mice suppress T-cell responses
via the generation of CD4+CD25+ regulatory T cells. This finding
provides novel input into the mechanisms of oral tolerance that
could further facilitate its use for the treatment of autoimmunity and
chronic inflammatory reactions.
Introduction
Oral tolerance refers to the immunological non-responsive-
ness to ingested protein antigens. Although the phenomenon
of immunological hyporesponsiveness following oral adminis-
tration of antigen has been known for more than 50 years, the
mechanisms of oral tolerance induction have still not been
elucidated fully. Nonetheless, it is generally accepted that
specialized antigen-presenting cells located at strategic
places in the gastrointestinal tract are responsible for oral
tolerance induction. Especially, professional antigen-present-
ing cells in the gut-associated lymphoid tissues, comprising
mesenteric lymph nodes, lamina propria, Peyer’s patches and
mucosal epithelium, are instrumental in tolerization to orally
taken antigens by either ‘anergy’ induction, deletion of
antigen-specific effector T cells, or by the induction of active
immune regulation. In the latter case, local generation of
regulatory T (Treg) cells is considered a plausible mechanism
responsible for immune hyporesponsiveness to the orally
administered antigens. Since oral administration of antigen
can lead to systemic unresponsiveness, it represents
potentially a powerful tool in the therapy of autoimmunity and
chronic inflammatory reactions. Therefore, a better under-
standing of the mechanisms of oral tolerance induction could
aid its use in the clinic, for example, in the treatment of
patients with rheumatic diseases. The current work presented
by Park and colleagues [1] provides further understanding on
the mechanisms underlying oral tolerance induction by
showing that indoleamine 2,3-dioxygenase (IDO)-expressing
dendritic cells (DCs) located in the gut are involved in the
inhibition of T-cell response and the generation of CD4+CD25+
Treg cells [1].
Treg cells are crucial regulators of peripheral self-tolerance.
They can suppress the effector functions of many cell types,
including T cells, B cells, and monocytes/macrophages in a
cell-contact dependent manner as well as via secretion of
soluble mediators, such as interleukin-10 and transforming
growth factor-β [2]. Moreover, they have the capacity to
inhibit arthritis, conceivably through the secretion of tumor
necrosis factor receptor II [3,4]. Treg cells can be generated
in the thymus upon confrontation with self-antigens presented
by thymic epithelial cells, as well as in peripheral lymphoid
tissues under specific conditions involving antigen presen-
tation in the absence of co-stimulation [2,5]. The transcription
factor forkhead box P3 (FOXP3) is essential for their
development and function, and represents a specific marker
for murine CD4+CD25+ Treg cells.
IDO in oral tolerance
IDO, an enzyme that degrades the essential amino acid
tryptophan, can be synthesized by many cell types. IDO-
expression is essential to maintain pregnancy as IDO-
deficiency or pharmacological inhibition of IDO results in
rapid T cell-induced rejection of allogeneic concepti, but is
also involved in the control of many other immunological
processes, such as tumor resistance, chronic infection,
autoimmunity and allergic inflammation [6]. During an immune
response, it can be expressed in response to, for example,
interferon-γ, and thereby is thought to protect the host from
collateral damage by suppressing T-cell responses [6]. The
immune regulatory function of IDO has been attributed mainly
to the reduction of local tryptophan concentration and the
generation of tryptophan metabolites [6].
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The article by Park and colleagues now shows that IDO can
also promote tolerance to orally administered collagen type II
in mice [1]. CD11c+ DCs in Peyer’s patches from orally
tolerized mice exhibit an immature phenotype and express
higher levels of IDO compared to those from control mice.
Functionally, they inhibit collagen type II-specific T cell
proliferation and pro-inflammatory Th1 cytokine production,
and more importantly, induce the generation of collagen type
II-specific CD4+CD25+FOXP3+ Treg cells from highly
purified CD4+CD25- T cells in an IDO-dependent manner.
Notably, the generation of Treg cells is antigen specific, as
IDO-expressing DCs without antigen have no effect [1].
These data are in line with recent findings showing that IDO-
expressing DCs can also directly activate resting
CD4+CD25+FOXP3+ Treg cells for potent suppressor
activity [7], and that cytotoxic T-lymphocyte antigen-4 and
glucocorticoid-inducible tumor necrosis factor receptor-
related protein, molecules highly expressed on CD4+CD25+
Treg cells, can induce IDO expression in DCs [8]. Together,
these results indicate that IDO-producing DCs and
CD4+CD25+ Treg cells may form a positive feedback loop in
the induction of oral tolerance [1,7,8].
However, although the combined effects of tryptophan
starvation and tryptophan catabolites may contribute to the
induction of CD4+CD25+ Treg cells by IDO [9], the position
of IDO in the induction of oral tolerance remains to be
determined. Notably, recent reports showing that retinoic
acid, a metabolite of vitamin A, produced by CD103+ DCs in
mesenteric lymph nodes promotes oral tolerance by enhan-
cing the transforming growth factor-β-dependent conversion
of naïve T cells into Treg cells [10] are of interest and pose
the question whether different subtypes of DCs (CD103
positive versus negative) or DCs located at different places of
the gut (mesenteric lymph nodes versus Peyer’s patches) use
different mechanisms (retinoic acid versus IDO) to induce
Treg cells. Furthermore, the relative contribution of these two
pathways in the induction of oral tolerance to defined
antigens remains to be determined.
Concluding remarks
The identification of the role of IDO-expressing DCs opens
another avenue to explore the possibility to treat human
autoimmunity and chronic inflammatory conditions by ‘preven-
tive’ vaccinations in an antigen-specific manner. However,
caution should be taken as the knowledge obtained from
mouse models can not be translated directly into human
subjects. Because contradicting data on the immuno-
regulatory role of IDO-producing human DCs have been
reported [11], further research is merited towards elucidating
the role of IDO-positive human DCs in oral tolerance
induction.
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